Background
Integrated DNA Technologies, Inc. appealed from a proceeding before the Patent Trial and Appeal Board, identified as IPR2025-00016. Tecan Genomics, Inc. was the appellee.
During the Federal Circuit proceedings, the parties agreed that the appeals should be dismissed. The court’s brief, nonprecedential order does not describe the underlying patent dispute or the Board’s decision.
The Court’s Holding
The Federal Circuit dismissed the proceeding under Federal Rule of Appellate Procedure 42(b) based on the parties’ agreement.
The court ordered each side to bear its own costs. It issued the order as the mandate on August 3, 2026, ending the appellate proceeding without addressing the merits.
Key Takeaways
- The appeals were dismissed by agreement under Federal Rule of Appellate Procedure 42(b).
- Each party must bear its own costs.
- The nonprecedential order did not decide any patent-law or inter partes review issue on the merits.
Why It Matters
The dismissal ends the Federal Circuit litigation arising from IPR2025-00016 without an appellate ruling on the underlying dispute. Because the order contains no merits analysis and is designated nonprecedential, it supplies no substantive guidance for other patent cases.